Ekf Diagnostics Share News (EKF)

LONDON (Alliance News) - EKF Diagnostics Holdings PLC on Monday said new data has been presented supporting the use of a soluble Tumour Necrosis Factor Receptor 1 as a biomarker in forecasting the progression of diabetic nephropathy, or diabetic kidney disease.

EKF said the study showed sTNFR1 can be used in clinical trials or therapeutic interventions designed to prevent or delay the progression of the disease to end-stage renal disease.

The biomarker was developed by EKF and the company part-funded the study. The data was presented at Kidney Week, held by the American Society for Nephrology.

"This large and exciting new data set confirms our own findings both here at EKF and with other collaborators. Having such impressive data presented at ASN puts us in front of the world's leading kidney specialists and will pave the way to the adoption of sTNFR1 as a routine test in the management of Diabetic Nephropathy," said EKF Chief Executive Julian Baines.

EKF shares were up 6.7% to 16.00 pence on Monday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.